The National Institute for Health and Care Excellence (NICE) has issued draft guidance on the funding of Celgene’s Abraxane to be used in combination with Lilly’s Gemzar in certain pancreatic cancer patients. NICE stated that the limited benefits as compared to current treatments do not justify its cost. What does this mean for pancreatic cancer patients in England and Wales? Find out here. (Source: Ben Adams, PMLiVE, 1/5/15).
You are here: / / What Does New NICE Decision Mean For Pancreatic Cancer Patients?